VAKCINA

siguran sam da je na to mislio, videlo se da je jedan peer reviewed razgovor u pitanju

eventualno ako je virus vrste zombi

Janko Suvar wrote:siguran sam da je na to mislio, videlo se da je jedan peer reviewed razgovor u pitanju

možda je samo preprint razgovora.

takodjer ako vam nesto znaci, moj dobar drug radi za BIA i kaze da je dobio Fajzerovu vackinu, bez da se prijavio, samo dosli i dali mu.

jel sa puškama?

Dosta me nervira što nikakve nuspojave nemam nedelju dana posle kineza. 20 min posle primanja sam imao trnce u usnama koji su prosli dok sam ih konstatovao, sledeca 24h periodican svrab ili tako nesto pod kožom i od tada apsolutno ništa. Poznanici neki koji su primili Rusa i Fajzera izgiboše, temperatura, lošost generalna, muka, jedna i bljuvala.

Da li moje debelo telo sa radošću dočekuje anti telašca ili ŠKK je ovo, voda za peglu u špricu?

To (J&J) je dobro kao emergency measure. Niko ko je dobio u probama nije ni umro ni primljen u bolnicu. Da je idealno - nije, ali ako nista znacajno ne daju ni rusi ni kinezi, a fajzer ostane sa 80tak hiljada doza mesecno...sve je bolje nego nista.

jos gore sa spricevima


i ja sam imao od Sinofarmove vakcine, blagi kontraefekat. Tako sto kazes losost, kao prehlada da pocinje, temperatura mozda malo. Proslo do kraja dana.

bukvalno nikakvu reakciju nisam imao od kineza, evo vec 2 nedelje otkako sam primio prvu.

osim sto sam nasao super prsluk u trznom centru panda

MNE wrote:pa tehnički gledano je tačno, jer sa vakcinom dobijaš umrtvljeni virus

Samo s kineskom.

glede dzonsona i dzonsona i ostalih ne bogznakako efikasnih vakcina, treba imati u vidu da je ovo samo prva godina vakcinacije. primicemo mi jos toga u buducnosti, za sada je bukvalno sve odlicno jer bukvalno sve smanjuje protok virusa kroz populaciju.

bemty wrote:glede dzonsona i dzonsona i ostalih ne bogznakako efikasnih vakcina, treba imati u vidu da je ovo samo prva godina vakcinacije. primicemo mi jos toga u buducnosti, za sada je bukvalno sve odlicno jer bukvalno sve smanjuje protok virusa kroz populaciju.

ma da, to uopste nije sporno. sad daj sta das, za 6 meseci, godinu dana...bice nesto drugo. J&J je bio ubacen u vatru ispitivanja u novembru, borio se i protiv novih sojeva...nisu to neki uzasno losi rezultati. Mislim, bilo sta sto te 100 posto spasava od bolnice, o smrti da ne pricam, je odlicno atm.

The data also show that a single dose delivers strong protection that — crucially — does not wane quickly.

12 weeks after the first dose, efficacy is still well above 70%. pic.twitter.com/nGbZWAAqJh

— John Burn-Murdoch (@jburnmurdoch) February 2, 2021

Full paper here: https://t.co/tiBEQAQcRe

And a big thanks to co-lead-author @MerrynVoysey for talking me through some of the finer points.

Scientists who respond instantly to DMs on deadline are possibly my favourite people in the world

— John Burn-Murdoch (@jburnmurdoch) February 2, 2021

jel peer reviewed? 

FDA considers speeding up approval process for vaccines targeting variants
...
The FDA has so far insisted that vaccine makers undertake months' worth of Phase 3 clinical trials before being authorised. But [the acting commissioner of the Food and Drug Administration Janet] Woodcock said on Thursday the agency was considering loosening those demands when evaluating vaccines that are based on existing technology but specifically target the new variants.

https://www.ft.com/content/184b9494-bec4-3ed9-ad84-fec396aee263

Johnson & Johnson on Thursday submitted to the FDA an application for emergency authorization for its one-dose coronavirus vaccine, putting the company on track to potentially begin shipping it by early March.https://t.co/UoRV9bj8rh

— The New York Times (@nytimes) February 5, 2021

Pakistan on Thursday said that China's Sinopharm vaccine is not effective for people over 60 years of age, a day after it began its countrywide coronavirus vaccination programme with the Chinese jabs.
China donated half a million doses of Sinopharm vaccines to Pakistan which sent a special plane to airlift the jabs on Monday.
Special Assistant to the Prime Minister on Health, Dr Faisal Sultan told the media on Thursday that Pakistan's expert committee while considering the preliminary analysis data recommended the vaccine only for people aged 18-60 years.
“At this stage, the expert committee has not authorised the Sinopharm vaccine for people older than 60,” he said, adding that after getting more data, a decision will be made whether it can be used for elderly.
Pakistan began its countrywide coronavirus vaccination programme on Wednesday...

https://timesofindia.indiatimes.com/world/pakistan/pakistan-says-chinas-sinopharm-vaccine-not-effective-for-people-over-60-years/articleshow/80691799.cms

France, Poland and Sweden on Tuesday issued recommendations not to use the COVID-19 vaccine developed by AstraZeneca for the elderly.

They join Germany and Italy which issued such recommendations last week.

Authorities in France and Sweden say the vaccine should be prioritised for people under the age of 65, both citing insufficient clinical trial data for older people.

"This recommendation will be re-examined in the light of the availability of additional data," France's national authority for health (HAS) said.

Sweden's public health agency said it expects such data "to come later in the spring from an ongoing and large US clinical trial in phase 3."

"It will include sufficient number of older participants to be able to draw more certain conclusions regarding the protective effect," it added.

Poland's government has set a lower threshold, recommending the use of the vaccine in people under the age of 60.

https://www.euronews.com/2021/02/03/france-poland-sweden-latest-eu-countries-to-rule-out-astrazeneca-jab-for-elderly

au

ja bih skrenuo paznju da je ovo times of india. tajvanski portali za sinofarm pisu da oslepis.

mislim uopste ima mnogo politikanstva oko vakcina.

tako na primer pakistan ce kao alternativu starijim za kineza ponuditi AZ za koji EU kaze da nije efikasan za 60+.

mislim svaka vakcina bustuje imunitet i to je to. spricajte se ljudi!

Marius Lăcătuș wrote:jel peer reviewed? 

rumbeando wrote:

France, Poland and Sweden on Tuesday issued recommendations not to use the COVID-19 vaccine developed by AstraZeneca for the elderly.

They join Germany and Italy which issued such recommendations last week.

Authorities in France and Sweden say the vaccine should be prioritised for people under the age of 65, both citing insufficient clinical trial data for older people.

"This recommendation will be re-examined in the light of the availability of additional data," France's national authority for health (HAS) said.

Sweden's public health agency said it expects such data "to come later in the spring from an ongoing and large US clinical trial in phase 3."

"It will include sufficient number of older participants to be able to draw more certain conclusions regarding the protective effect," it added.

Poland's government has set a lower threshold, recommending the use of the vaccine in people under the age of 60.

https://www.euronews.com/2021/02/03/france-poland-sweden-latest-eu-countries-to-rule-out-astrazeneca-jab-for-elderly

boomer crook wrote:mislim svaka vakcina bustuje imunitet i to je to. spricajte se ljudi!

Ajde da preskocimo.times of india (koji sam ja skoro zabranila na mom google news feed-u), ali postoje razlozi zasto se "pustanje vakcine u realnost" ne radi pre dobijanja pouzdanih rezultata iz kontrolisanih studija. Nakon sto pustis vakcinu u realnost mozes da radis samo observational studije, a one ti ne mogu reci jel radis dobru stvar sa vakcinom ili prosto tog trenutka imas srece (ako ti je teend pozitivan). A ako pustis u realnost vakcinu bez dokazane efektivnosti pa se ispostavi da ona ustvari bas i nije efikasna koliko treba, ne samo da si potrosio resurse na neefikasnu vakcinu i dao javnosti lazni osecaj sigurnosti, vec, u teoriji, rizikujes i scenario gde vakcina nije dovoljno dobra da obuzda virus ali ima dovoljno efekta na imuni sistem da blokira rad neke mozda efikasnije vakcine.
Ja razumem da konda zuljaju kapitalisticki razlozi za zbrku sa vakcinama u EU, ali ne traze se podaci iz kontrolisanih studija zbog kapitalizma. U ovoj situaciji sa AZ, sigurnije je reci "daj AZ mladjima a starijima fajzer", a to mozemo da znamo samo zbog postojanja kontrolisanih studija, ne "pustanja u realnost".

Za 5 sekundi može se pronaći gomila pakistanskih izvora sa istom vešću, dovoljno je ukucati faisal sultan sinopharm i obaviti pretragu na .pk domenu.

U tekstu postoji konflikt informacija. "Not effective" vs. "after getting more data, a decision will be made whether it can be used for elderly".

U osnovi, nemaju dovoljno podataka o uspehu vakcine kod starijih od 60, isti slučaj kao i sa AstroZekom.

Kad ste se već laćali geopolitike: sama činjenica da Pakistan odbija da vakciniše savezničkom kineskom vakcinom dobijenom na poklon (link) određenu starosnu grupu i umesto nje preporučuje vakcinu firme koja se uortačila s njihovim neprijateljem Indijom kako bi proizvela milijarde doza ukazuje na to da je problem tu veći, verovatno takođe nema dovoljno podataka, ali ono što je dostupno kazuje da je verovatnoća da efikasnost bude zadovoljavajuća osetno manja nego kod oksfordske.

Ne, već je pogrešna medijska interpretacija, kao što sam već rekao. Jednostavno ne mogu da znaju jer klinička studija nije obuhvatila 60+.

Naravno postavlja se pitanje zašto su kod nas drugačije preporuke iako su zasnovane na istoj dokumentaciji. Može se očekivati da će raditi i na starijima, ali malo transparentnosti nije na odmet.

“Some people have misinterpreted the guidelines of the vaccine. The fact is that it is a research-based recommendation that people over 60 years of age should not be vaccinated. The clinical trial of vaccine was held on people from 18 to 60 years of age; so as per protocols, people of the same age group should be vaccinated. It does not mean that the vaccine is not safe for people of over 60 years of age. They can be vaccinated once the company releases data regarding clinical trial on them,” NHS ministry’s spokesperson Sajid Shah said while talking to Dawn.